The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Reinforced Adversarial Neural Computer for de Novo Molecular Design
Open accessAbstract
In silico modeling is a crucial milestone in modern drug design and development. Although computer-aided approaches in this field are well-studied, the application of deep learning methods in this research area is at the beginning. In this work, we present an original deep neural network (DNN) architecture named RANC (Reinforced Adversarial Neural Computer) for the de novo design of novel small-molecule organic structures based on the generative adversarial network (GAN) paradigm and reinforcement learning (RL). As a generator RANC uses a differentiable neural computer (DNC), a category of neural networks, with increased generation capabilities due to the addition of an explicit memory bank, which can mitigate common problems found in adversarial settings. The comparative results have shown that RANC trained on the SMILES string representation of the molecules outperforms its first DNN-based counterpart ORGANIC by several metrics relevant to drug discovery: the number of unique structures, passing medicinal chemistry filters (MCFs), Muegge criteria, and high QED scores. RANC is able to generate structures that match the distributions of the key chemical features/descriptors (e.g., MW, logP, TPSA) and lengths of the SMILES strings in the training data set. Therefore, RANC can be reasonably regarded as a promising starting point to develop novel molecules with activity against different biological targets or pathways. In addition, this approach allows scientists to save time and covers a broad chemical space populated with novel and diverse compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Hybrid computing using a neural network with dynamic external memory
Graves, A., Wayne, G., Reynolds, M., Harley, T., Danihelka, I., Grabska-Barwińska, A., Colmenarejo, S. G., Grefenstette, E., Ramalho, T., Agapiou, J., et al. (2016) · Nature · doi:10.1038/nature20101 · Cited by 1,412
From machine learning to deep learning: progress in machine intelligence for rational drug discovery
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.010 · Cited by 760
Deep Learning in Drug Discovery
Gawehn, E., Hiss, J. A., & Schneider, G. (2016) · Molecular Informatics · doi:10.1002/minf.201501008 · Cited by 723
Applications of Deep Learning in Biomedicine
Mamoshina, P., Vieira, A., Lane, E., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00982 · Cited by 701
Self-citationPastur-Romay, L., Cedrón, F., Pazos, A., & Porto-Pazos, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081313 · Cited by 109
Research works printed but not linked: 37
- Holenz J., 2016, Lead Generation, Vol. 68: Methods and Strategies, 2, 10.1002/9783527677047 · doi:10.1002/9783527677047
- 10.1038/aps.2011.173 · DOI · Paper page
- 10.1002/cpch.27 · DOI
- 10.1038/aps.2015.108 · DOI
- Mannhold R., 2014, Drug Metabolism Prediction, 63
- Balakin K. V., 2009, Pharmaceutical Data Mining: Approaches and Applications for Drug Discovery, 6, 10.1002/9780470567623 · doi:10.1002/9780470567623
- 10.1007/978-1-60761-274-2_2 · doi:10.1007/978-1-60761-274-2_2
- 10.1080/13543776.2017.1272573 · doi:10.1080/13543776.2017.1272573
- 10.1038/nrd1799 · DOI · Paper page
- 10.1093/bib/bbw068 · DOI · Paper page
- 10.1002/minf.201700111 · DOI · Paper page
- 10.1021/acs.jcim.6b00754 · DOI
- 10.1021/acs.molpharmaceut.7b00578 · DOI · Paper page
- 10.1021/acs.molpharmaceut.6b00248 · DOI · Paper page
- Bjerrum E. J., 2017, arXiv.org, 1705.04612v2
- Gómez-Bombarelli R., 2016, arXiv.org, 1610.02415
- Guimaraes G. L., 2017, arXiv.org, 1705.10843
- 10.1186/s13321-017-0235-x · DOI · Paper page
- 10.26434/chemrxiv.5309668.v3 · DOI
- Goodfellow I., 2014, Adv. Neural Inf. Proc. Syst., 2672
- Arjovsky M., 2017, arXiv.org, 1701.04862
- Arjovsky M., 2017, arXiv.org, 1701.07875
- Popova M., 2017, arXiv.org, 1711.10907
- Graves A., 2014, arXiv.org, 1410.5401
- Weston J., 2015, arXiv.org, 1502.05698
- Yu, L.; Zhang, W.; Wang, J.; Yu, Y. SeqGAN: Sequence Generative Adversarial Nets With Policy Gradient. Proceedings of the Thirty-First AAAI Conference on Artificial Intelligence (AAAI-17) ; 2017; pp 2852–2858. · DOI · Paper page
- Sutton R. S., 2000, Adv. Neural Inf. Process. Syst., 1057
- Zhang X., 2015, arXiv.org, 1502.01710
- 10.1021/ci3001277 · DOI · Paper page
- 10.1021/ci0100649 · DOI
- 10.1039/c1ob06065a · DOI
- 10.2174/1389200054021799 · DOI · Paper page
- 10.1021/ci100050t · DOI · Paper page
- 10.1007/s10822-015-9872-1 · DOI
- Abadi M., 2016, arxiv.org, 1605.08695
- 10.1002/med.10041 · DOI · Paper page
- 10.1038/nchem.1243 · DOI · Paper page
Cited by
Artificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Self-citationRecent advances and applications of deep learning methods in materials science
Choudhary, K., DeCost, B., Chen, C., Jain, A., Tavazza, F., Cohn, R., Park, C. W., Choudhary, A., Agrawal, A., Billinge, S. J. L., et al. (2022) · npj Computational Materials · doi:10.1038/s41524-022-00734-6 · Cited by 1,172
“There have also been several applications for identifying reasonable chemical space using DL methods such as autoenco-ders 111 and reinforcement learning 112 – 114 for inverse materials design.”
MethodGuacaMol: Benchmarking Models for de Novo Molecular Design
Brown, N., Fiscato, M., Segler, M. H. S., & Vaucher, A. C. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00839 · Cited by 895
Deep learning for molecular design—a review of the state of the art
Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00039a · Cited by 683
Mater, A. C., & Coote, M. L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00266 · Cited by 565
Opportunities and Challenges for Machine Learning in Materials Science
Morgan, D., & Jacobs, R. (2020) · Annual Review of Materials Research · doi:10.1146/annurev-matsci-070218-010015 · Cited by 549
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365
Self-citationPotential of quantum computing for drug discovery
Cao, Y., Romero, J., & Aspuru-Guzik, A. (2018) · IBM Journal of Research and Development · doi:10.1147/jrd.2018.2888987 · Cited by 357
Self-citationArtificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development
Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032026 · Cited by 347
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery
Polykovskiy, D., Zhebrak, A., Vetrov, D., Ivanenkov, Y., Aladinskiy, V., Mamoshina, P., Bozdaganyan, M., Aliper, A., Zhavoronkov, A., & Kadurin, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00839 · Cited by 278
Self-citationThe transformational role of GPU computing and deep learning in drug discovery
Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00463-x · Cited by 255
Artificial intelligence for aging and longevity research: Recent advances and perspectives
Zhavoronkov, A., Mamoshina, P., Vanhaelen, Q., Scheibye-Knudsen, M., Moskalev, A., & Aliper, A. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.003 · Cited by 246
“Although relatively new, GANs have already been applied in various fi elds, including making predictions of compound properties or for molecular structure generation (Kadurin et al., 2017b; Kadurin et al., 2017a; Polykovskiy et al., 2018; Zhavoronkov et al., 2018a,b).”
Chemistry42: An AI-Driven Platform for Molecular Design and Optimization
Ivanenkov, Y. A., Polykovskiy, D., Bezrukov, D., Zagribelnyy, B., Aladinskiy, V., Kamya, P., Aliper, A., Ren, F., & Zhavoronkov, A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01191 · Cited by 231
Self-citationAccelerating antibiotic discovery through artificial intelligence
Melo, M. C. R., Maasch, J. R. M. A., & de la Fuente-Nunez, C. (2021) · Communications Biology · doi:10.1038/s42003-021-02586-0 · Cited by 234
Generative molecular design in low data regimes
Moret, M., Friedrich, L., Grisoni, F., Merk, D., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-0160-y · Cited by 219
Unleashing the power of generative AI in drug discovery
Gangwal, A., & Lavecchia, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103992 · Cited by 195
Biohorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities
Galkin, F., Mamoshina, P., Aliper, A., de Magalhães, J. P., Gladyshev, V. N., & Zhavoronkov, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101050 · Cited by 189
Self-citationGenerative machine learning for de novo drug discovery: A systematic review
Martinelli, D. D. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105403 · Cited by 177
The Advent of Generative Chemistry
Vanhaelen, Q., Lin, Y.-C., & Zhavoronkov, A. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00088 · Cited by 151
Self-citationHe, S., Leanse, L. G., & Feng, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113922 · Cited by 141
Quantum computing for near-term applications in generative chemistry and drug discovery.
Pyrkov, A., Aliper, A., Bezrukov, D., Lin, Y.-C., Polykovskiy, D., Kamya, P., Ren, F., & Zhavoronkov, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103675 · Cited by 100
Self-citationVerkhivker, G. M., Agajanian, S., Hu, G., & Tao, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00136 · Cited by 76
Machine intelligence in cardiovascular medicine
Miller, D. D. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000294 · Cited by 58
Metadata
- Authors
- Putin, E., Asadulaev, A., Ivanenkov, Y., Aladinskiy, V., Sanchez-Lengeling, B., Aspuru-Guzik, A., & Zhavoronkov, A.
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-05-15
- Volume
- 58
- Issue
- 6
- Pages
- 1194-1204
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2805002767
- Cited by
- 372
- References
- 8
- FWCI
- 30.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Tata Steel
- Ministry of Education and Science of the Russian Federation (20.9907.2017/VU)
- Government of the Russian Federation (074-U01)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
